Yep. His first purchase was at over 4 and a half bucks a share. To some degree A part of me is surprised that he didn’t bail out of this investment as he has done with other stocks he has invested in. From the appearances of the way things are moving in ROW, it seems clear now that the US market is the most likely thing to move the stock in the magnitude we are hoping for. The insurance coverage changes are a step in the right direction but it is not enough. We need a legal avenue to come through to either shut the Generics out or have them abandon GV. Maybe the new formulation could do it, but I know virtually nothing wrt the company’s plan for it nor how far down the road it would be. Some here are younger than I and can wait it out more than I. Here’s to hoping we discover their plan of action before at least the end of 2026.
Market Data 
Markets 
AI
